Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder January 6, 2026
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer October 22, 2025
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit October 16, 2025
